Skip to content

H.R. 2369 · 118th Congress (2023–2025)

VALID Act of 2023

This bill requires the Food and Drug Administration (FDA) to regulate in vitro clinical tests (IVCTs).

Currently, the FDA and the Centers for Medicare & Medicaid Services have authority to regulate in vitro diagnostic devices. The bill defines IVCTs, which includes in vitro diagnostic devices, as tests intended for the collection, preparation, analysis, or in vitro clinical examination of specimens from the human body to provide information about a disease, condition, or treatment.

An IVCT may not be introduced into interstate commerce unless it has received FDA premarket approval or is covered by certain exemptions, such as an exemption for a test that (1) was developed and introduced before this bill's enactment and meets certain requirements, (2) is a low-risk test, (3) is solely for public health surveillance, (4) is covered by a technology certification issued under this bill, or (5) has received a humanitarian exemption or emergency use authorization.

The FDA may grant upon application a technology certification. Generally, such a certification covers a group of tests that use a single technology and may be evaluated using a representative test. While such a certification is valid, a qualifying IVCT that falls within the scope of the certification shall be cleared for interstate commerce.

The bill also imposes various requirements related to IVCTs, including those related to quality control, labeling, and reporting adverse events.

The FDA shall have various enforcement authority, including authority to order the recall of an IVCT with a reasonable probability of causing serious adverse health consequences.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act with respect to in vitro clinical tests, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 2369’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Larry Bucshon (R-IN-8)
Cosponsors
3 cosponsors

1 original · 2 later

  1. Rep. Diana DeGette (D-CO-1)· Original · Mar 29, 2023
  2. Rep. Thomas H. Kean, Jr. (R-NJ-7)· Later · May 11, 2023
  3. Rep. Anna G. Eshoo (D-CA-16)· Later · Mar 21, 2024
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Mar 29, 2023 – Apr 7, 2023
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 29, 2023
  2. HouseHealthReferred Apr 7, 2023
  3. HouseWays and MeansReferred Mar 29, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. VALID Act of 2023

    Display title, Short title · Introduced in House

  2. Verifying Accurate Leading-edge IVCT Development Act of 2023

    Short title · Introduced in House

  3. To amend the Federal Food, Drug, and Cosmetic Act with respect to in vitro clinical tests, and for other purposes.

    Official title · Introduced in House